Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes

Heller S, Battelino T, Bailey TS, et al.
Diabetes Obes Metab.Pub. online 24 Jan 2023.

Associations of disordered eating with the intestinal microbiota and short-chain fatty acids among young adults with type 1 diabetes

Igudesman D, Crandell J, Corbin KD, et al.
Nutr Metab Cardiovasc Dis. 2023;33(2):388-398.

LDL-cholesterol control in the primary prevention of cardiovascular diseases: An expert opinion for clinicians and health professionals

Poli A, Catapano AL,  Corsini A, et al.
Nutr Metab Cardiovasc Dis. 2023;33(2):245-257.

Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial

Feig DS, Sanchez JJ, Murphy KE, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(23)00004-9.

Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels

D’Andrea E, Wexler DJ, Kim SC, et al.
JAMA Intern Med. Pub. online 6 Feb 2023.

Frias J, Chien J, Zhang Q, et al.
Lancet Diabetes Endocrinol. Pub. online 6 Feb 2023.

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

Laffel LM, Danne T, Klingensmith GJ, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(22)00387-4.

Association of elevated arterial stiffness with cardiac target organ damage and cardiac autonomic neuropathy in young adults with diabetes: the SEARCH for diabetes in youth study

Urbina EM, Isom S, Dabelea D, et al.
Diabetes Care. 2023;dc221703.

Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality

Persson S, Nilsson K, Karlsdotter K, et al.
Diabetes Obes Metab. 2023;25(3):726-734.

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies

Zheng D, Li N, Hou R, et al.
BMC Med. 2023 Feb 3;21(1):40